Yes, Alector stock has experienced substantial volatility since its public market debut, which is typical for clinical-stage biotechnology equities. Its share price swings are frequently catalyzed by clinical trial updates, regulatory announcements, interim data readouts from major neurological studies, and broader macroeconomic shifts affecting the biotech sector. Positive pipeline advancements or major partnership milestones often drive sharp upward rallies, while clinical setbacks or trial discontinuations can trigger significant downward corrections.